



STATE OF OKLAHOMA  
OKLAHOMA HEALTH CARE AUTHORITY

OHCA 2016-30

October 21, 2016

**RE: Removal of Prior Authorization of Neulasta®**

Dear SoonerCare Provider,

On October 5, 2016, SoonerCare removed the prior authorization for Neulasta® (pegfilgrastim). Numerous inquiries regarding the prior authorization of Neulasta® were received by SoonerCare, and after a review of data the decision was made to remove the prior authorization requirement. SoonerCare reserves the right to reinstate the prior authorization of Neulasta® in the future.

Prior authorization guidelines are located on the OHCA website, [Pharmacy Prior Authorizations](#), in the "biologic" therapeutic category and are as follows:

- An FDA approved diagnosis; and
- A patient-specific, clinically significant reason why the member cannot use Neupogen® (filgrastim) or Neulasta® (pegfilgrastim).

Neupogen® and Neulasta® will not require a prior authorization.

If the member requires Granix® (tbo-filgrastim) or Zarxio™ (filgrastim-sndz) through either a pharmacy or medical claim, a manual prior authorization form must be submitted. These forms can be located on the forms page on the OHCA website at [OHCA Forms](#). Please use PHARM-04 for pharmacy requests and PHARM-18 for medical requests.

All medication prior authorization requests are processed by the Pharmacy Authorization Unit.

If you have questions, please contact the pharmacy authorization unit at (800) 522-0114, option 4.

Thank you for your continued service to Oklahoma's SoonerCare members.

Sincerely,

A handwritten signature in cursive script that reads "Rebecca Pasternik-Ikard".

Rebecca Pasternik-Ikard  
Chief Executive Officer